Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Randomized Controlled Study of Azacitidine Combined With Homoharringtonine Compared With Azacitidine for Patients With Int/High -Risk MDS and AML-MRC

NCT03978364 is registered in ClinicalTrials.gov with Shandong Provincial Hospital as lead sponsor.

NCT NCT03978364
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03978364 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Randomized Controlled Study of Azacitidine Combined With Homoharringtonine Compared With Azacitidine for Patients With Int/High -Risk MDS and AML-MRC
Lead sponsor
Shandong Provincial Hospital
Phase
Phase 3
Overall status
Unknown status
Start date
June 1, 2019
Completion date
December 31, 2022
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndromes,acute myeloid leukemia